Sera Prognostics says PRIME trial shows PreTRM-guided care cuts preterm births before 32 weeks by over 50%
SERA•Potential payer interest as coverage expands
The trial also showed fewer neonatal intensive care admissions, a potential driver of payer interest given the high cost of NICU stays.
The update comes as coverage expands, including Illinois Medicaid coverage for proteomic prenatal testing effective July 1, 2026.
PRIME trial results support PreTRM-guided care
Sera Prognostics highlighted results from the PRIME randomized trial evaluating PreTRM Test-guided care in about 5,000 pregnancies.
Results were already published, positioning the study as evidence to support broader clinical adoption of the company’s blood test.
PreTRM-guided care was associated with fewer of the earliest, highest-risk premature births, supporting earlier intervention planning in routine obstetric care.
